Company intelligence / Profile preview

Allucent

Ownership: Private
Development stage: Commercial

Overview

Allucent has supported over a thousand clinical trials across more than seventy countries with deep expertise in complex disease areas. The majority of its work centers on oncology and advanced therapeutic modalities for small to mid-sized biotech clients. It provides end-to-end services including regulatory consulting, trial design/execution from preclinical to post-marketing phases. No proprietary clinical results as it does not own drug assets.

Therapeutic areas: ImmunologyHematologyOncologyRare DiseasesNeurology
Modalities: Small moleculesMonoclonal antibodies (mAbs)Bispecific antibodiesAntibody-drug conjugates (ADCs)Cell therapiesGene therapiesNanoparticle formulationsVaccines (anticancer vaccines)
Industry: Contract Research Organization

Beyond the preview

Go deeper on Allucent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allucent.

Explore the full profile